The neurotoxin market has fractured into five distinct products, each with real clinical and economic differences that shape your inventory, pricing, and patient outcomes. Botox (onabotulinumtoxinA) remains the reference standard and volume leader, but Dysport (abobotulinumtoxinA), Jeuveau (prabotulinumtoxinA), Daxxify (daxibotulinumtoxinA), and Xeomin (incobotulinumtoxinA) have carved niches based on onset speed, duration, diffusion profile, and cost. For a practice owner, the choice is not about which is "best"—it's about understanding the pharmacology and economics well enough to stock the right mix, educate patients accurately, and defend your pricing to payers and patients alike. This guide walks you through the clinical and financial realities.
Reference Guide
Neurotoxin Comparison: Botox vs Dysport vs Jeuveau vs Daxxify vs Xeomin
Head-to-head breakdown of onset, duration, dosing, diffusion, and acquisition cost across the five FDA-cleared neuromodulators—what to stock and how to price.